Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
| ▸ | TUBB | P07437 | 2/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18472614 | 1.00 | ACHE (0.59) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL14432911 | 0.85 | PTGS2 (0.50) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL10209878 | 0.84 | TSHR (0.50) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL29951473 | 0.80 | TUBB4A (0.44) | ACHECYP3A4MAPTCA9PTGS2 | |
| SCHEMBL31538431 | 0.79 | ERN1 (0.49) | CYP3A4MAPTHTR2CALDH1A1L3MBTL1 | |
| SCHEMBL13929520 | 0.78 | MEN1 (0.41) | ACHECYP3A4MAPTCA9ALDH1A1 | |
| SCHEMBL10751466 | 0.77 | CYP3A4 (0.53) | ACHECYP3A4MAPTPTGS2ALDH1A1 | |
| SCHEMBL9787558 | 0.77 | PKM (0.49) | CYP3A4MAPTHTR2CALDH1A1L3MBTL1 | |
| SCHEMBL9933825 | 0.77 | TUBB4A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31038744 | 0.77 | CYP3A4 (0.40) | ACHECYP3A4MAPTCA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2579870-B1 | TRKB AGONISTS AND METHODS OF USE | UNIV EMORY (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170036980-A1 | COPPER CATALYZED [18F]FLUORINATION OF IODONIUM SALTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-02-09 | — | — | US | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504674-B2 | TrkB agonists and methods of use | EMORY UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| US-9029561-B2 | TRKB agonists and methods of use | EMORY UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029561-B2 | TRKB agonists and methods of use | EMORY UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011156479-A9 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2011156479-A2 | TRKB AGONISTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040947-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | ACHE 1910/4885CYP3A4 1228/4885MAPT 1145/4885 |
| US-20150174107-A1 | TRKB AGONISTS AND METHODS OF USE | NTRK2, BDNF, NTRK1 | ACHE 1765/4885CYP3A4 1323/4885MAPT 1003/4885 |
| US-20170036980-A1 | COPPER CATALYZED [18F]FLUORINATION OF IODONIUM SALTS | SOD1, TPO, FLI1 | ACHE 1413/4885CYP3A4 510/4885MAPT 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.